OTC · Health care

CytoDyn Inc. (CYDY)

It posted a net loss of $42.7M. At May 31, 2026 it held $11.9M in cash against $38.3M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on August 31, 2026.

Watch CYDY in 60 seconds

Price

$0.21

-7.31% on the day · September 28, 2026

52-week range $0.18 to $0.40

Market cap

$290.2M

What CytoDyn Inc. does

CytoDyn Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CYDY.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	n/a	-$38.6M	-$42.7M	-$0.03	n/a
2025	n/a	$9.7M	$3.7M	$0.00	n/a
2024	n/a	-$18.1M	-$49.8M	-$0.05	n/a
2023	$0	-$40.6M	-$79.8M	-$0.10	n/a
2022	$266K	-$145.4M	-$210.8M	-$0.31	n/a
2021	$0	-$104.6M	-$176.5M	-$0.30	-$117.7M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 30, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 31, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What CytoDyn Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
Shelf registration to sell securities S-3
September 25, 2026
Form POS AM filing POS AM
September 25, 2026
Form POS AM filing POS AM
August 31, 2026
Annual report 10-K · period to May 31, 2026Diluted EPS -$0.03 versus $0.00.
May 20, 2026
Securities offering prospectus 424B3
April 30, 2026
Investor disclosure 8-K
April 22, 2026
IPO registration S-1
April 8, 2026
Securities offering prospectus 424B3
April 8, 2026
Quarterly report 10-Q · period to February 28, 2026Diluted EPS $0.00 versus $0.00.
March 25, 2026
Securities offering prospectus 424B3

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 24, 2026. Insider transactions on SEC

Insider trades

What the people running CytoDyn Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about CYDY

What does CytoDyn Inc. do?

CytoDyn Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CYDY.

Is CytoDyn Inc. profitable?

No. In fiscal 2026 it reported a net loss of $42.7M.

When did CytoDyn Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on August 31, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the shelf registration to sell securities from September 25, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare CYDY with

Compare CYDY with any company

Follow CYDY

Get an email when CytoDyn Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CYDY: get an email when it files

Where the numbers come from

Financial figures are the values CytoDyn Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.